Capital Research Global Investors Madrigal Pharmaceuticals, Inc. Transaction History

Capital Research Global Investors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $36.5 Million - $49 Million	-466,422 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$97.2 - $137.59 $139 Million - $196 Million	-1,426,644 Reduced 75.36%	466,422 $45.4 Million
Q1 2021 May 14, 2021	BUY	$108.54 - $125.2 $247,362 - $285,330	2,279 Added 0.12%	1,893,066 $221 Million
Q4 2020 Feb 12, 2021	BUY	$110.06 - $133.7 $600,927 - $730,001	5,460 Added 0.29%	1,890,787 $210 Million
Q3 2020 Nov 13, 2020	BUY	$99.78 - $124.21 $18.8 Million - $23.4 Million	188,208 Added 11.09%	1,885,327 $224 Million
Q4 2019 Feb 18, 2020	BUY	$84.28 - $118.5 $1.17 Million - $1.64 Million	13,850 Added 0.82%	1,697,119 $155 Million
Q3 2019 Nov 14, 2019	BUY	$84.4 - $106.53 $590 - $745	7 Added 0.0%	1,683,269 $145 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $1.71 Million - $2.68 Million	18,810 Added 1.13%	1,683,262 $176 Million
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $61 Million - $88.4 Million	294,200 Added 21.47%	1,664,452 $356 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $37.9 Million - $117 Million	373,359 Added 37.45%	1,370,252 $383 Million
Q1 2018 May 15, 2018	BUY	$93.35 - $149.04 $93.1 Million - $149 Million	996,893 New	996,893 $116 Million

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.35B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

Stay updated on Capital Research Global Investors with notifications on news.